About The Study: Receiving at least two doses of wild-type BNT162b2 vaccine (Pfizer) was associated with a reduced risk of COVID-19 emergency department or urgent care and outpatient visits in children younger than five years. The risk of SARS-CoV-2 encounters appeared lower for those with two versus three doses of BNT162b2, albeit with wide CIs, which is likely due to more immune-evasive Omicron sublineages (e.g., BQ.1-related and XBB-related strains) becoming dominant by the time young children received their third dose and longer median time since dose three compared with dose two.
Authors: Sara Y. Tartof, Ph.D., M.P.H., of the Kaiser Permanente Southern California Department of Research & Evaluation in Pasadena, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.17473)
